New therapeutics that modulate chemokine networks

被引:132
作者
Schwarz, MK [1 ]
Wells, TNC [1 ]
机构
[1] Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland
关键词
D O I
10.1038/nrd795
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Chemokines are small cytokines that control a wide variety of biological and pathological processes, from immunosurveillance to inflammation, and from viral infection to cancer The numerous known chemokine receptors have given hope that selective receptor antagonism might be possible, which could allow us to control which cells are recruited and activated at any time and in any place. As chemokine receptors are G-protein-coupled receptors, which are classical targets for the pharmaceutical industry, it is hoped that chemokines could be the first cytokines for which small-molecule receptor antagonists could be developed. Recently, reports of chemokine-receptor antagonists, both in vitro and in animal models of disease, have been published. It is anticipated that this field could produce clinically useful therapies in the next few years.
引用
收藏
页码:347 / 358
页数:12
相关论文
共 97 条
[1]   A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation [J].
Anders, HJ ;
Vielhauer, V ;
Frink, M ;
Linde, Y ;
Cohen, CD ;
Blattner, SM ;
Kretzler, M ;
Strutz, F ;
Mack, M ;
Gröne, HJ ;
Onuffer, J ;
Horuk, R ;
Nelson, PJ ;
Schlöndorff, D .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (02) :251-259
[2]  
Auten RL, 2001, J PHARMACOL EXP THER, V299, P90
[3]   A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity [J].
Baba, M ;
Nishimura, O ;
Kanzaki, N ;
Okamoto, M ;
Sawada, H ;
Iizawa, Y ;
Shiraishi, M ;
Aramaki, Y ;
Okonogi, K ;
Ogawa, Y ;
Meguro, K ;
Fujino, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (10) :5698-5703
[4]  
Berger EA, 1997, AIDS, V11, pS3
[5]  
Boring L, 1999, CONT IMMUN, V8, P53
[6]   Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-8 replication by antagonism of the chemokine receptor CXCR4 [J].
Bridger, GJ ;
Skerlj, RT ;
Padmanabhan, S ;
Martellucci, SA ;
Henson, GW ;
Struyf, S ;
Witvrouw, M ;
Schols, D ;
De Clercq, E .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (19) :3971-3981
[7]   Randomized phase-II study of BB-10010 (macrophage inflammatory protein-1α) in patients with advanced breast cancer receiving 5-fluorouracil, adriamycin, and cyclophosphamide chemotherapy [J].
Clemons, MJ ;
Marshall, E ;
Dürig, J ;
Watanabe, K ;
Howell, A ;
Miles, D ;
Earl, H ;
Kiernan, J ;
Griffiths, A ;
Towlson, K ;
DeTakats, P ;
Testa, NG ;
Dougal, M ;
Hunter, MG ;
Wood, LM ;
Czaplewski, LG ;
Millar, A ;
Dexter, TM ;
Lord, BI .
BLOOD, 1998, 92 (05) :1532-1540
[8]   ANALYSIS OF HYDROPHOBICITY IN THE ALPHA-CHEMOKINE AND BETA-CHEMOKINE FAMILIES AND ITS RELEVANCE TO DIMERIZATION [J].
COVELL, DG ;
SMYTHERS, GW ;
GRONENBORN, AM ;
CLORE, GM .
PROTEIN SCIENCE, 1994, 3 (11) :2064-2072
[9]   Nicotinamide N-oxides as CXCR2 antagonists [J].
Cutshall, NS ;
Ursino, R ;
Kucera, KA ;
Latham, J ;
Ihle, NC .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (14) :1951-1954
[10]   Discovery of potent and selective phenylalanine derived CCR3 receptor antagonists. Part 2 [J].
Dhanak, D ;
Christmann, LT ;
Darcy, MG ;
Keenan, RM ;
Knight, SD ;
Lee, J ;
Ridgers, LH ;
Sarau, HM ;
Shah, DH ;
White, JR ;
Zhang, LL .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (11) :1445-1450